Articles from Aarvik Therapeutics

Aarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that it will present two posters and a minisymposium talk at the AACR Annual Meeting 2026. These presentations display the breadth of Aarvik’s capabilities in the ADC space. The AACR Annual Meeting will take place from April 17-22, 2026, in San Diego, California.

Aarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce an investment by Laurus Labs, India in Aarvik’s recently-concluded Series Seed 2 financing round.

Aarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that it has successfully closed a Series Seed 2 financing round.

Aarvik Therapeutics, a biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that its collaboration partner ArriVent BioPharma, Inc. has exercised the option to exclusively license the collaboration program.

Aarvik Therapeutics announces a global license and assignment Agreement with NJ Bio, Inc. to secure a class of novel proprietary payloads with a wide range of potencies.

Aarvik Therapeutics announced the recent publication by Sachdev Sidhu, Ph.D., Co-founder of Aarvik Therapeutics, and his colleagues of a study validating the novel tetravalent antibody platform that forms a core component of innovation at Aarvik. This study by Miersch et al. uses modular design principles to combine neutralizing antibodies against two independent epitopes of the SARS-COV-2 spike protein into a single bi-paratopic, tetravalent antibody. The tetravalent antibody behaves like conventional IgGs on yield, purity, stability, and solubility but demonstrates potency and breadth of coverage that far exceed conventional bivalent IgGs. This tetravalent antibody platform offers enormous potential not just in infectious disease but also in oncology and other therapeutic areas.

Aarvik Therapeutics, a biotechnology company dedicated to engineering precision medicines for cancer therapy, is excited to announce that Richard Scheller, PhD has joined as an Independent Board Member and Scientific Advisory Board (SAB) Chair.

Aarvik Therapeutics, a biotechnology company dedicated to engineering precision therapies for oncology targets, has undergone a name change from Aarkus Therapeutics, effective immediately.